PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
KANE, Christopher J
Professor of Surgery and Chief of Urology
eRA COMMONS USER NAME (credential, e.g., agency login)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
(if applicable)
University of California, Davis
Uniformed Services University of the Health
Sciences, Bethesda, MD
University of California, Davis East Bay Surgery
Residency, Oakland, CA
Oakland Naval Hospital, CA
Mechanical Engineering
Surgical Internship
Urology Residency
A. Personal Statement
My research interests are primarily prostate cancer and kidney cancer risk assessment and outcomes. I am
currently collaborating with the world-renowned lab of Dr. Michael Karin, Dr. Christina Jamieson and Dr. Steve
Howell, designing studies to examine the inhibition of B-cell recruitment and CXCL13/CXCR5 signaling in prostate
cancer. We are particularly interested in translating the remarkable discoveries of the Karin lab into meaningful
therapeutics for men with prostate cancer. My surgical expertise is in robot-assisted prostatectomy, open and
laparoscopic kidney cancer surgery, and bladder and testes cancer surgery. I am one of the most experienced
prostate cancer surgeons in California, performing over 150 radical prostatectomies annually. I have taught
laparoscopy and robotic surgery extensively, started the robotic surgery programs at UC San Francisco and the VA
Medical Center San Francisco, and significantly expanded the robotic surgery program at UC San Diego.
B. Positions and Honors
Staff Urologist, Naval Medical Center San Diego
Principal Investigator, Center for Prostate Disease Research
Residency Director, Urology, Naval Medical Center San Diego
Clinical Instructor of Surgery, Uniformed Services University (USUHS)
Assistant Professor of Surgery, Uniformed Services University (USUHS)
Associate Professor of Urology, University of California, San Francisco
Chief of Urology, VA Medical Center San Francisco
Professor of Urology, UC San Francisco
Professor of Surgery and Urology Residency Program Director, UCSD School of Medicine
Chief of Urology, UC San Diego Health System
Director of Robotic Surgery, UC San Diego Health System
GU Oncology Team Leader, UC San Diego Moores Comprehensive Cancer Center
C. Lowell and JoEllen Parsons Endowed Chair in Urology, UCSD School of Medicine
Vice Chief of Staff, UCSD Medical Staff
Honors (selected)
Navy Commendation Medal (Urology Residency Leadership)
Meritorious Service Medal (Hospital Wide and National Navy Leadership)
William Smart Teaching Award for Outstanding Faculty Teacher in the Department of
Urology, University of California, San Francisco
Examination Committee Member for the American Board of Urology
San Diego’s Top Doctors, San Diego Magazine (with San Diego Medical Society)
Physician Healthcare Champion of the Year for San Diego, San Diego Business Journal
Reviewer Roll of Honor, British Journal of Urology, International
Distinguished Engineering Alumni Medal, UC Davis College of Engineering
Top Urologists, U.S. News & World Report
C. Selected Peer-Reviewed Publications (15 most relevant from more than 185)
1. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ,
Carroll PR. Multi-institutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of
recurrence after radical prostatectomy. Cancer 2006;107(10):2384-2391.
2. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic
hyperplasia. N Engl J Med. 2006 Feb 9;354(6):557-66.
3. Boorjian S, Cowan JE, Konety BR, Duchane J, Tewari A, Carroll PR, Kane CJ; Cancer of the Prostate Strategic
Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer:
results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007;177(3):883-888.
4. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold LA, Humphreys E,
Epstein JI, Partin AW, Freedland SJ. Clinical and pathologic outcome after radical prostatectomy for prostate cancer
patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006;107:1265-1272.
5. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ; SEARCH Database Study Group.
Changing nature of high-risk patients undergoing radical prostatectomy. J Urol. 2007;177(1):113-117.
6. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC
Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration
among men with prostate cancer. JAMA. 2007;298:2275-2280.
7. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR, Kane CJ. Effect of BMI on Primary Treatment
of Prostate Cancer. Urology. 2008;72(2):406-411.
8. Breyer BN, Greene KL, Dall’Era MA, Davies BJ, Kane CJ. Pelvic Lymphadenectomy in Prostate Cancer. Prostate
Cancer Prostatic Dis. 2008;11(4):320-324.
9. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, Kane CJ. Impact of nerve sparing on
surgical margins and biochemical recurrence: results from the SEARCH database. Prostate Cancer Prostatic Dis.
10. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, Freedland SJ. Outcomes after radical
prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology.
11. Silberstein JL, Parsons JK, Palazzi-Churas K, Downs TM, Sakamoto K, Derweesh IH, Woldrich J, Kane CJ.
Robot-assisted laparoscopic radical prostatectomy in men with human immunodeficiency virus. Prostate Cancer
Prostatic Dis. 2010;13(4):328-332.
12. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared
Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010;116(14):3389-3398.
13. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA,
Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patient-derived intra-femoral xenograft model of bone
metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.J Transl Med. 2011;9:185198.
14. Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC, Amling CL,
Kane CJ. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol. 2012
15. Stroup SP, Kane CJ. Robot-assisted laparoscopic prostatectomy for high-risk prostate cancer: technical
considerations and review of the literature. ISRN Urol. 2011; 7 pages [Epub Sept 25; PubMed PMID: 22084791].
D. Research Support
Ongoing Research Support
Astellas/Protocol 905-UC-050 (Kane C)
10/17/2011 – present
0.0 Calendar
Astellas Pharmaceuticals
A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy and
Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted
Radical Prostatectomy
Major goals: To explore the effectiveness and safety of the United States Food and Drug Administration (FDA)
approved drug VESIcare® (Solifenacin Succinate) compared to placebo (inactive drug) on post prostatectomy
incontinence; in patients who have recently undergone a robotic-assisted radical prostatectomy.
CALGB 90203 (Millard F)
NIH/NCI – Cancer and Leukemia Group B
05/17/2007 – present
0.0 Calendar
Role: Sub-Investigator
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical
Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate
Major goals: To determine whether treatment with neoadjuvant docetaxel and androgen deprivation therapy prior
to radical prostatectomy will increase the rate of 3-year biochemical progression-free survival (bPFS) compared
to treatment with immediate radical prostatectomy alone for high-risk prostate cancer patients.
Reimbursement: $2,000/patient
Phi Delta Psi Charity Trust (Jamieson C)
07/01/2012 – 03/31/2013
0.0 Calendar
Phi Delta Psi Charity Trust
Bone-niche and Castration-resistant Prostate Cancer
Role: Co - Principal Investigator
Major goals: To develop novel in vivo and in vitro models for castration-resistant prostate cancer in the bone niche
using primary prostate cancers and bone metastases to identify biomarkers and targets for molecular therapy.
No salary may be supported with this award.
1R01EB014929 - 01A1 (Nguyen Q)
07/01/2012 – 06/30/2017
0.6 Calendar
NIH - National Institute of Biomedical Imaging and Bioengineering
Testing Fluorescently Labeled Probes for Nerve Imaging during Surgery
Role: Co-Investigator
Major goals: To develop novel fluorescent peptides to visualize nerves in situ during surgery including nerve-sparing
Pfizer (Karin M)
07/01/2012 – 06/30/2015
0.0 Calendar
Inhibition of B cell Recruitment and CXCL13/CXCR5 Signaling in Prostate Cancer
Role: Clinical Collaborator
Major goals: To determine the utility of CXCR5 blockade in castrate-resistant prostate cancer.
Funding Agency: UCSD Moores Cancer Center Translational Cancer Research
Funding Period: 4/15/11 – 4/14/12
Title: Robotic Sentinel Lymph Node Mapping via Detection of a Receptor-Targeted Molecular Imaging Probe
Role: Co–Principal Investigator
Funding Agency: NIH
Funding Period: 2005-2010
Title: Evaluation of predictive signatures of prostate cancer. (PI: Wang-Rodriguez, J.)
Role: Co-Investigator
Goals: To develop a complete and comprehensive clinical data set of patients with a diagnosis of prostate
carcinoma and to correlate molecular biomarkers with clinical outcome.
Funding Agency: VA Cooperative Group, CSP 407, PIVOT Trial
Funding Period: 1995-2007
Title: A randomized trial comparing radical prostatectomy versus palliative expectant management for the treatment
of clinically localized prostate cancer.
Role: Site PI
Goals: The primary objective of this study is to determine which of two strategies is superior for the management of
clinically localized prostate cancer: 1) radical prostatectomy with early aggressive intervention for disease
persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of
symptomatic or metastatic disease progression.
Funding Agency: VA Cooperative Group, CSP 553
Funding Period: 2006-2007
Title: Chemotherapy after prostatectomy for high risk prostate cancer.
Role: Site PI
Goals: To prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone
added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk
for relapse.
Funding Agency: Southwest Oncology Group
Funding Period: 7/25/01-2007
Title: Selenium and vitamin E cancer prevention trial.
Role: Site PI
Goals: To determine whether selenium, vitamin E, or both prevent prostate cancer.